A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- the change in urinary protein-creatinine ratio from baseline to the end of study
研究概览
简要总结
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
详细描述
Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio > 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 24 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 2years or older and younger than 18 years
- •Biopsy-proven Ig A Nephropathy
- •Estimated GFR ≥ 90mL/min/m^2
- •Mean urinary protein-creatinine ratio > 0.3 g/g from three first-morning spot urine collections
排除标准
- •hypertension
- •under dialysis or organ transplanted
- •bilateral renal artery stenosis
- •primary hyperaldosteronism
研究组 & 干预措施
Losartan treatement
All patients had received losartan treatment for 24 weeks.
干预措施: Losartan (Drug)
结局指标
主要结局
the change in urinary protein-creatinine ratio from baseline to the end of study
时间窗: 24weeks
Change in urinary protein excretion, determined as urinary protein-creatinine ratio compared to baseline, after 24 weeks of treatment.
次要结局
- the proportion of patients wifh urinary protein-creatinine ratio < 0.2 at the end of study(24 weeks)
- the change in urinary albumin-creatinine ratio from baseline to the end of study(24 weeks)
- the proportion of patients wifh more than 50% decrease of urinary protein-creatinine ratio(24 weeks)